CHICAGO — A novel oral aryl hydrocarbon receptor inhibitor appeared well tolerated and safe among a small cohort of patients with advanced solid tumors, according to phase 1 study results presented at ASCO Annual Meeting.In addition, the initial evaluation of biomarkers confirmed the biologic activity of BAY 2416964 (Bayer).